BioAge Labs’ Post

The human gut microbiome, crucial for health, remains largely uncultured. High-throughput sequencing revolutionizes understanding, aiding in therapies and diagnostics. Herein, we discuss the current state and future directions of metagenomics. 📖 Human Gut Microbiome: Metagenomic Insights and Prospectus Kyle D. Brumfield and Nur Hasan 🔗 read in full at the Journal of Applied Microbiomics 👉 https://lnkd.in/eer6YdS9

Thrilled to share our paper (The Role of Punicalagin and Its Metabolites in Atherosclerosis and Risk Factors Associated with the Disease). This paper reveals how these natural compounds, particularly from pomegranates, combat key drivers of cardiovascular disease, including inflammation, oxidative stress, and endothelial dysfunction. Discover more about this promising approach in the International Journal of Molecular Sciences https://lnkd.in/dTmFEaUk. #Research #CardiovascularHealth #Atherosclerosis #NaturalCompounds #Innovation

Accurately determining how many people are affected by rare conditions is challenging, but studies using large-scale genetic databases are turning the tide. These powerful analyses, as conducted by HealthLumen for conditions such as #FabryDisease, and other conditions with a genetic basis, provide the robust data needed at each stage of the drug development lifecycle, helping to accelerate the process, so that rare disease patients gain faster access to the therapies they need. To read the article, visit https://bit.ly/4biFToI

Accurately determining how many people are affected by rare conditions is challenging, but studies using large-scale genetic databases are turning the tide. These powerful analyses, as conducted by HealthLumen for conditions such as #FabryDisease, and other conditions with a genetic basis, provide the robust data needed at each stage of the drug development lifecycle, helping to accelerate the process, so that rare disease patients gain faster access to the therapies they need. To read the article, visit https://bit.ly/4biFToI

Lipidomics, the study of fats in the body, is a key area of focus for us. This is a rapidly growing field of science and a critical one because lipids play a big part in regulating our metabolism and our risk of disease. Here's a brief insight into our lipidomics work. You can also check out the Metabolomics group to find out what projects they are working on. ▶️https://lnkd.in/g7sfnpCX

As the complexity of human diseases continues to rise, the importance of studying and prioritizing 3D culture cell models has never been greater. Disease-specific organoids offer advantages over traditional 2D cultures as they are better at recapitulating structure and behavior. However, the following disadvantages can minimize the success of 3D cell models for clinical research. Learn more: https://ow.ly/VkOi50Svnlk #sartorius #criticalchallenges #3dmodels #diseasemodels

🧬 𝗪𝗵𝗮𝘁 𝗶𝗳 𝘆𝗼𝘂 𝗰𝗼𝘂𝗹𝗱 𝘁𝗮𝗶𝗹𝗼𝗿 𝘄𝗲𝗶𝗴𝗵𝘁 𝗺𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗽𝗹𝗮𝗻𝘀 𝘁𝗼 𝘆𝗼𝘂𝗿 𝗽𝗮𝘁𝗶𝗲𝗻𝘁𝘀’ 𝗴𝗲𝗻𝗲𝘁𝗶𝗰𝘀 𝗳𝗼𝗿 𝘀𝘂𝘀𝘁𝗮𝗶𝗻𝗮𝗯𝗹𝗲 𝗿𝗲𝘀𝘂𝗹𝘁𝘀? Join Sascha Landskron, MSc, BSc, RD, and Laura Vila Vecilla, Ph.D., to discover how Nutrigenomics can help you revolutionize your patient care. 📅 𝗥𝗲𝗴𝗶𝘀𝘁𝗲𝗿 𝗻𝗼𝘄 for the November 18th webinar and get actionable insights: https://lnkd.in/dcWDph7f Letting Genes Trigger Treatments #nutrigenomics #genetictesting #NutriGen #personalizedmedicine #FagronGenomics

Resalis in a nutshell: We have summarized key facts about our company in a comprehensive factsheet. This resource includes essential scientific data, an explanation of our pioneering non-coding RNA approach, and the next steps for our lead candidate, RES-010. We invite you to explore our journey and the transformative potential of our work in metabolic diseases. Stay tuned for more updates and breakthroughs from Resalis!

Did you know that most of the current available therapies do not work for every person with cystic fibrosis , particularly leaving behind those whose disease is caused by rare variants? A recent review paper, first-authored and coordinated by Margarida Amaral, group leader of the Cystic Fiborsis Research Lab (at Faculdade de Ciências da Universidade de Lisboa), co-authored by Ines Pankonien (researcher of the same lab) and published in the Journal of Cystic Fibrosis, proposes integrating two approaches, theratyping (using lab-grown cell lines) and theranostics (using patient-derived samples), as way to expand treatment options and establish a more personalized and effective treatment option for more, if not all, people with this disease. Know more by reading this #BioISIDigest: https://bioisi.pt/news/94 Read the full paper: https://bit.ly/3UepdbX #CysticFibrosis #Theranostics #Theratyping #RareMutations

Many high value targets remain undrugged because they lack sufficient structure to be drugged by small molecules. The hub protein 14-3-3 has a vast interactome, including many high value undrugged targets and importantly, has a druggable interface. Our molecular glues unlock these high value targets, creating new therapeutic options for patients across disease areas.   Learn more about our science: https://lnkd.in/eNVsNuR3